Abbvie Joins UK Dementia Consortium

The pharmaceutical company AbbVie is the newest member to join the UK Dementia Consortium, a £4 initiative to identify new treatment for dementia, including Alzheimer’s disease, ALS and frontotemporal dementia (FTD). Other participants are the pharmaceutical companies Eisai, Lilly and Astex, the research charity MRC Technology, and the non-profit organization Alzheimer’s Research UK (see Sept 2015 news). The consortium has already funded several projects, including a study developing novel approaches to target TDP-43 toxicity in ALS and FTD.

Click here to read more.

disease-ad disease-als disease-ftd topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail